About this trial
The purpose of this study, performed under the master protocol W8M-MC- CWMM (NCT06143956), is to evaluate the efficacy and safety of LY4086940 compared with placebo in participants without type 2 diabetes who have obesity or who have overweight with a weight-related health condition.
Participation in the study will last about 58 weeks.
Eligibility criteria
This trial does not accept healthy volunteersQualifiers
Meet inclusion criteria under Master Protocol CWMM (NCT06143956)
Disqualifiers
Have any prior diagnosis of type 2 diabetes, type 1 diabetes, or rare forms of diabetes mellitus, except gestational diabetes
Have a laboratory value suggestive of diabetes
acute myocardial infarction
cerebrovascular accident (stroke)
Trial design
Parallel
Treatments tested in this trial
LY4086940
DrugAdministered orally
Placebo
DrugAdministered orally
Treatment groups
10
Treatment groupsSee each treatment group below.
Trial outcomes
Primary outcomes
Percent Change from Baseline in Body Weight
Secondary outcomes
Percent Change from Baseline in Body Weight
Change from Baseline Impact of Weight on Quality of Life-Lite Clinical Trials Version (IWQOL-Lite-CT)
Pharmacokinetics (PK): Area Under the Curve (AUC) of LY4086940 for One Dosing Interval at Steady State
PK: Maximum Concentration (Cmax) of LY4086940 at Steady State
Sponsors and contacts
Click on the lead sponsor to view all of their trials.
This trial is not recruiting at the moment. You can still explore other options: